Perindopril Protection Against Recurrent Stroke Study "PROGRESS"

Completed

Phase N/A Results

Trial Description

To compare the angiotensin-converting enzyme (ACE) inhibitor perindopril, alone or in combination with the diuretic indapamide, to placebo in the secondary prevention of stroke and other major cardiovascular events.

Interventions

  • Antihypertensives Drug
    Intervention Desc: This category includes all BP lowering drugs in stroke prevention trials
  • Perindopril (Aceon)Drug
    Intervention Desc: Antihypertensive; angiotensin converting enzyme (ACE) inhibitor

Trial Design

Randomized, double-blind, placebo-controlled, international, trial of 6105 patients at 172 centers.

Patient Involvement

Patients were randomly assigned to treatment with the ACE inhibitor perindopril 4 mg or placebo, plus the diuretic indapamide (for individuals in whom it was not considered to be definitely indicated or contraindicated) or placebo.

Outcomes

Type Measure Time Frame Safety Issue
Primary Total number of strokes defined by WHO criteria.
Secondary Fatal and disabling strokes, total number of cardiovascular events and deaths, cognitive function, disability, and dependency. Mean follow-up is 3 years.

Sponsors

Health Research Council of New Zealand, National Health and Medical Research Council of Australia, Institut de Recherches Internationales Servier